Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

(2010) Roy T. Steigbigel et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetic Interaction of Ritonavir-Boosted Elvitegravir and Maraviroc

(2010) Srinivasan Ramanathan et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial

(2010) Andrew R. Zolopa et al.   JOURNAL OF INFECTIOUS DISEASES

Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy

(2009) Damian J. McColl et al.   ANTIVIRAL RESEARCH

Clinical Pharmacokinetics and Pharmacodynamics of Etravirine

(2009) Monika Schöller-Gyüre et al.   CLINICAL PHARMACOKINETICS

Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study

(2009) Ping Zhao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Emerging Pharmacology: Inhibitors of Human Immunodeficiency Virus Integration

(2008) Daria Hazuda et al.   Annual Review of Pharmacology and Toxicology

Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers

(2008) Vanitha J. Sekar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

(2008) Samantha Abel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Maraviroc:in vitroassessment of drug-drug interaction potential

(2008) Ruth Hyland et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Impact of Different Low-Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression

(2008) S Collot-Teixeira et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure

(2008) AA Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of Elvitegravir

(2008) Anita A Mathias et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES